Catalyst Wire Dossier Catalyst Wire Dossier

Sodium Hyaluronate 1.2%

sodium hyaluronate · Ferring Pharmaceuticals
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Sodium Hyaluronate 1.2%, covering 2012-06-04 to 2012-06-04. Get the full timeline:

Most recent: Clinical Trial Update: Investigation of 1.2% Sodium Hyaluronate for Treatment of Painful Chronic Osteoarthritis of the Knee [Phase 3]

See pricing